Anbio BiotechnologyNNNN +2.88%24 Days Payable is 14.56 as of Dec. 2025, which is 93% below its 10-year median of 194.56. GuruFocus rates NNNN with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Anbio Biotechnology ranks better than 86.42% on this metric.
The historical rank and industry rank for Anbio Biotechnology's Days Payable or its related term are showing as below:
NNNN'
s Days Payable Range Over the Past 10 Years
Min: 54.81 Med: 194.56 Max: 537.25
Current: 238.48
During the past 5 years, Anbio Biotechnology's highest Days Payable was 537.25. The lowest was 54.81. And the median was 194.56.
NNNN's Days Payable is ranked better than 86.42% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs NNNN: 238.48
Anbio Biotechnology's Days Payable
declined
from Dec. 2024 (531.83) to Dec. 2025 (14.56).
It may suggest that Anbio Biotechnologyaccelerated paying its suppliers.
Anbio Biotechnology Days Payable Related Terms
Anbio Biotechnology Days Payable Historical Data
* Premium members only.
The historical data trend for Anbio Biotechnology's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Anbio Biotechnology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anbio Biotechnology Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anbio Biotechnology's Days Payable distribution charts can be found below:
* The bar in red indicates where Anbio Biotechnology's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Anbio Biotechnology's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anbio Biotechnology (NNNN) has a Days Payable of 14.56 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Anbio Biotechnology and its competitors. This is 93% below median its historical median of 194.56. Over the past decade, Anbio Biotechnology's Days Payable has ranged from 54.81 to 537.25. According to the industry distribution chart, Anbio Biotechnology ranks #108 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 13.6%.
Is Anbio Biotechnology's Days Payable too high?
Anbio Biotechnology's current Days Payable of 14.56 is 93% below median its 10-year median of 194.56. Over the past 10 years, this metric has ranged from a low of 54.81 to a high of 537.25. The Medical Devices & Instruments industry median Days Payable is 68.07. Anbio Biotechnology's value of 14.56 is 78.6% below this industry median. Based on the distribution chart, Anbio Biotechnology ranks #108 out of 795 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's Days Payable compare to ANGO and OSUR?
According to the Medical Devices & Instruments industry distribution chart, Anbio Biotechnology ranks #108 out of 795 companies for Days Payable. This places Anbio Biotechnology in the top 14% of its industry — outperforming the majority of peers. The industry median Days Payable is 68.07. Anbio Biotechnology's value of 14.56 is 78.6% below this benchmark. Historically, Anbio Biotechnology's own Days Payable has ranged from 54.81 to 537.25 over the past decade. While the company's 10-year median is 194.56 vs. the industry median of 68.07, Anbio Biotechnology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anbio Biotechnology's current Days Payable of 14.56 is 78.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Anbio Biotechnology and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anbio Biotechnology's current Days Payable is 14.56, which is 93% below median its own 10-year median of 194.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (NNNN) has a current Days Payable of 14.56. The current Days Payable is 14.56, which is 93% below median its 10-year median of 194.56 and 78.6% below the Medical Devices & Instruments industry median of 68.07. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Anbio Biotechnology (NNNN), the current Days Payable is 14.56 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score
Get the complete analysis for NNNN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNNN has been successfully added to your 
